GeneDx Holdings (WGS) Share-based Compensation (2020 - 2026)

GeneDx Holdings (WGS) has reported Share-based Compensation for 7 consecutive years, with $3.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 58.38% year-over-year to $3.3 million in Q2 2026; TTM through Jun 2026 was $35.7 million, a 95.35% increase from a year earlier, with the FY2025 full-year figure at $32.2 million, up 251.96% from the prior year.
• Share-based Compensation was $3.3 million for Q2 2026 at GeneDx Holdings, down from $12.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $154.4 million in Q2 2022 and troughed at -$6.1 million in Q4 2023.
• A 5-year average of $15.3 million and a median of $4.0 million in 2025 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 29857.42% in 2022 and slumped 1039.58% in 2024, its largest moves.
• Over 5 years, Share-based Compensation stood at $154.4 million in 2022, then sank by 103.92% to -$6.1 million in 2023, then soared by 146.99% to $2.8 million in 2024, then surged by 243.76% to $9.8 million in 2025, then tumbled by 66.75% to $3.3 million in 2026.
• The last three Share-based Compensation figures came in at $3.3 million (Q2 2026), $12.1 million (Q1 2026), and $9.8 million (Q4 2025), per Business Quant data.